Author

Emily A. Kaymen

Observed names: E.A., Kaymen, Emily Kaymen

Institution: Cedars-Sinai Medical Center

Observed institution: Cedars-Sinai Medical Center

ORCID: 0000-0003-3415-6575

Observed ORCID: 0000-0003-3415-6575

OpenAlex ID: A5090286504

Immune-Related Adverse Events Are Associated With Improved Outcomes After Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

2025 · Soo Young Hwang, Mohammad Saeid Rezaee-Zavareh, et al. · The American Journal of Gastroenterology · 12

Curative Treatment after Immunotherapy Leads to Excellent Outcomes in Patients with Hepatocellular Carcinoma

2025 · Gwang Hyeon Choi, Hyun-Seok Kim, et al. · Liver Cancer · 4

Clinical outcome after complete response with immunotherapy in hepatocellular carcinoma.

2025 · Pin-Jung Chen, Ioannis Kournoutas, et al. · Journal of Clinical Oncology · 1

Real-world comparison of atezolizumab/bevacizumab vs durvalumab/tremelimumab in decompensated hepatocellular carcinoma.

2026 · Yu-Han Chen, Wee Han Ng, et al. · Journal of Clinical Oncology

Association between immune-related adverse events and prognosis after immune checkpoint inhibitor in hepatocellular carcinoma: A meta-analysis and systematic review.

2025 · Soo Young Hwang, Mohammad Saeid Rezaee-Zavareh, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 17

H-index: 2

I10-index: 1